<i>Helicobacter pylori</i> infection as a risk factor in the development of metabolic dysfunction-associated steatotic liver disease

The problem of metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a non-infectious pandemic, the growth drivers of which are obesity and diabetes mellitus. According to modern concepts, MASLD develops and progresses as a result of the interaction of multiple genetic, environmental and adaptive factors, which include specific genetic polymorphisms (for example, the patatin-like phospholipase domain-containing protein 3 gene) and epigenetic modifications, dietary patterns (for example, high consumption of saturated fats and fructose), physical inactivity, obesity, insulin resistance, dysregulation of adipokine production, lipotoxicity, oxidative stress, intestinal microbiota dysbiosis (small intestinal bacterial overgrowth syndrome). In addition, due to the high infection rate of <i>Helicobacter pylori</i> (up to 80%) of people in the population, the influence of this factor on the development and progression of MASLD cannot be ruled out. Ye <i>et al</i> presented a study investigating the relationship between <i>Helicobacter pylori</i> infection and metabolic dysfunction associated with hepatic steatosis and identified prognostic factors. Certainly, the work of the Chinese authors deserves attention and further study.